3rd Retinal Imaging Biomarkers & Endpoints Summit

The 3rd Retinal Imaging Biomarkers & Endpoints Summit is scheduled for May 27–29, 2025, in Boston, Massachusetts. This premier event brings together leading experts in ophthalmology, imaging science, and regulatory affairs to discuss the latest advancements in retinal imaging technologies. Attendees will explore how cutting-edge imaging biomarkers can enhance clinical trial design, improve patient selection, and accelerate regulatory approvals for retinal diseases such as age-related macular degeneration (AMD), diabetic macular edema (DME), and geographic atrophy (GA). The summit emphasizes the integration of artificial intelligence (AI) and deep learning systems to revolutionize retinal imaging and analysis.

Participants will have the opportunity to engage with key opinion leaders from renowned institutions and companies, including REGENXBIO, Bausch + Lomb, Novartis, Alexion, and Cedars-Sinai Medical Center. The event will feature case studies, panel discussions, and networking sessions aimed at fostering collaborations and sharing insights on overcoming regulatory challenges, identifying clinically meaningful endpoints, and implementing advanced imaging techniques in clinical practice.

Focus Areas:

• Advancements in retinal imaging technologies
• Integration of AI and deep learning in imaging analysis
• Development and validation of imaging biomarkers
• Regulatory considerations for imaging endpoints

Notable Speakers:

• Archana Nigalye – Associate Director, Medical, Alexion
• Ash Jayagopal – Chief Scientific & Development Officer, Opus Genetics
• Maryam Mokhtarzadeh – Senior Director, Regulatory Strategy, REGENXBIO
• Mayssa Attar – Senior Vice President & Head of Pharmaceutical, Consumer Research & Development, Bausch + Lomb

Participating Organizations:

• REGENXBIO
• Bausch + Lomb
• Novartis
• Alexion
• Cedars-Sinai Medical Center